Health
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies, which assessed the efficacy and safety of ICOTYDE™ (icotrokinra) in the treatment of patients with moderate-to-severe plaque psoriasis (PsO). ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
About this update from Johnson & Johnson
[{"type":"text","content":"Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies","length":151,"tagName":"p"},{"type":"text","content":"Nearly 60% of adolescents treated with ICOTYDE achieved completely clear skin at Week 52 in the ICONIC-LEAD study","length":113,"tagName":"p"},{"type":"text","content":"SPRING HOUSE, Pa., March 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies, which assessed the efficacy and safety of ICOTYDE™ (icotrokinra) in the treatment of patients with moderate-to-severe plaque psoriasis (PsO). ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.","length":530,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":37,"url":"https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7hpY7JPUXNlbdaYud9s0jQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY1/https://media.zenfs.com/en/prnewswire.com/f6c13e47c55b1b30082ae2cdc7f55cf9","width":400,"height":37}},"href":"https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo_v1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"ICOTYDE achieved high levels of complete skin clearance up to Week 52 with no new safety signals2,a","length":99,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In the ICOTYDE treatment arms, rates of completely clear skin (PASI 100) increased from 41% to 49% and 33% to 48% from Week 24 to Week 52 in ADVANCE 1 and 2, respectively.a,b","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"Patients who switched from placebo to ICOTYDE at Week 16 achieved similar rates of complete skin clearance by Week 52 (50% and 43% in ADVANCE 1 and 2, respectively) as those who were treated with ICOTYDE for the full 52 weeks.","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"The ICOTYDE adverse event profile through Week ...